CompaniesAscenta Therapeutics

Ascenta Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (12)
View all

Total Trials

12

As Lead Sponsor

10

As Collaborator

2

Total Enrollment

605

By Phase

PHASE1: 2PHASE2: 6PHASE1/PHASE2: 4

By Status

COMPLETED: 8TERMINATED: 3WITHDRAWN: 1
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Today
NCT00275431
NCT00286793
NCT00440388
NCT00397293
NCT00561197
NCT00571675
NCT00934076
Hover over trial bars to see details

Recent Trials

NCT01265199Lead Sponsor
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
PHASE1Terminated
29 participants
Started: Feb 28, 2011 · Completed: Jan 31, 2013
NCT00934076Collaborator
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
PHASE1Withdrawn
Started: Feb 28, 2010 · Completed: Jun 30, 2015
NCT00988169Collaborator
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
PHASE2Terminated
6 participants
Started: Sep 30, 2009 · Completed: May 31, 2010
NCT00571675Lead Sponsor
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
PHASE2Completed
220 participants
Started: Oct 31, 2007 · Completed: Sep 30, 2010
NCT00544960Lead Sponsor
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
PHASE2Completed
106 participants
Started: Sep 30, 2007 · Completed: Apr 30, 2009
View all 12 trials →